GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

Strona główna・Stock List・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Closed

288.45 1.26

Buy Sell

Overview

Share price change

24h

Current

Min

286.85

Max

289.85

Key metrics
By Trading Economics
Income	22B 49B
Sales	18B 97B
P/E Sector Avg	10.403 49.701
EPS	10.91
Dividend yield	4.09
Profit margin	50.15
Employees	67,900
EBITDA	32B 69B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+9.53% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	4.09% 2.39%
Next Earnings	5 sie 2026
Next Ex Dividend date	13 sie 2026

Market Stats
By TradingEconomics
Market Cap	8.6B 1.3T
Previous open	287.19
Previous close	288.45

Novo Nordisk A-S (Class B) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 maj 2026, 15:48 UTC

Acquisitions, Mergers, Takeovers

Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence

6 maj 2026, 07:30 UTC

Earnings

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6 maj 2026, 06:19 UTC

Earnings

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

18 maj 2026, 13:10 UTC

Market Talk

Earnings

Novo Nordisk Report Shows Bright Spots Amid Price Pressure -- Market Talk

12 maj 2026, 12:05 UTC

Hot Stocks

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 maj 2026, 10:51 UTC

Hot Stocks

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 maj 2026, 09:42 UTC

Earnings

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

12 maj 2026, 09:08 UTC

Hot Stocks

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

11 maj 2026, 20:30 UTC

Earnings

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

7 maj 2026, 09:30 UTC

Earnings

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 maj 2026, 12:36 UTC

Earnings

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 maj 2026, 10:53 UTC

Hot Stocks

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 maj 2026, 10:12 UTC

Earnings

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 maj 2026, 09:58 UTC

Earnings

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6 maj 2026, 09:35 UTC

Hot Stocks

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 maj 2026, 08:13 UTC

Market Talk

Earnings

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6 maj 2026, 07:43 UTC

Market Talk

Earnings

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6 maj 2026, 07:00 UTC

Earnings

Novo Nordisk Shares Rise 5.5% After 1Q Results

6 maj 2026, 06:34 UTC

Earnings

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6 maj 2026, 06:26 UTC

Earnings

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6 maj 2026, 06:26 UTC

Earnings

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6 maj 2026, 06:24 UTC

Earnings

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6 maj 2026, 06:20 UTC

Earnings

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6 maj 2026, 06:19 UTC

Earnings

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6 maj 2026, 06:13 UTC

Earnings

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6 maj 2026, 06:13 UTC

Earnings

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6 maj 2026, 06:12 UTC

Earnings

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6 maj 2026, 05:43 UTC

Earnings

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

6 maj 2026, 05:42 UTC

Earnings

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

6 maj 2026, 05:40 UTC

Earnings

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

Peer Comparison

Price change

Novo Nordisk A-S (Class B) Forecast

Price Target

By TipRanks

9.53% upside

12 Months Forecast

Average 1,162.73 DKK 9.53%

High 1,550 DKK

Low 720 DKK

Based on 11 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S (Class B) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Novo Nordisk A-S (Class B) - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.